Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The safety Survey of pneumonitis induced by the combination of platinum, pemetrexed and pembrolizumab in chemo-naive non-small cell lung cancer patient in the real-world setting

Next Previous
Search
Trial Profile

The safety Survey of pneumonitis induced by the combination of platinum, pemetrexed and pembrolizumab in chemo-naive non-small cell lung cancer patient in the real-world setting

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Platinum complexes (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms SUSPECT

Most Recent Events

  • 30 Apr 2021 Status changed from active, no longer recruiting to completed.
  • 20 Apr 2021 Results published in the European Journal of Cancer
  • 24 Mar 2020 Status changed from not yet recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top